SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001493152-24-028400
Filing Date
2024-07-18
Accepted
2024-07-18 21:35:14
Documents
2
Period of Report
2023-05-24

Document Format Files

Seq Description Document Type Size
1 ownership.html 4  
1 ownership.xml 4 4440
2 ex24.htm EX-24 9548
  Complete submission text file 0001493152-24-028400.txt   15509
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Issuer) CIK: 0001859007 (see all company filings)

IRS No.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O ZYVERSA THERAPEUTICS, INC. 2200 N. COMMERCE PARKWAY WESTON FL 33326
Business Address
Cashmere Karen A. (Reporting) CIK: 0001954546 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-41184 | Film No.: 241125926